Open AccessSafety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials
Author(s) -
Hermann Haller,
Stefano Bianchi,
Kieran McCafferty,
Susan Arthur,
Carol Moreno Quinn,
Jeffrey Budden,
Matthew R. Weir
Publication year - 2022
Publication title -
kidney360
Language(s) - English
Resource type - Journals
ISSN - 2641-7650
DOI - 10.34067/kid.0001562022
Subject(s) - hyperkalemia , medicine , kidney disease , adverse effect , subgroup analysis , renal function , spironolactone , randomized controlled trial , stage (stratigraphy) , urology , aldosterone , confidence interval , paleontology , biology
Hyperkalemia is a common electrolyte abnormality in patients with CKD, which is associated with worse outcomes and limits use of renin-angiotensin-aldosterone system inhibitors (RAASi). This post hoc subgroup analysis of three clinical trials evaluated the efficacy and safety of the sodium-free, potassium-binding polymer, patiromer, for the treatment of hyperkalemia in adults with nondialysis CKD.